Frontlight ResearchEarly access
CompletedNo phase
Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
Key facts
- Who runs it
- Bharat Serums and Vaccines Limited
- Where
- India40 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT07680413
- CTRI/2025/12/099964
- Status
- Completed
- People taking part
- 660 people enrolled
- Started
- 31 Dec 2025
- Ended
- 3 Aug 2026
- Type of study
- Observational
- Treatments tested
- Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection
- Record updated
- 2 October 2026
Who can take part
- Age
- 13 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male or female patients aged ≥13 years
- Able and willing to provide written informed consent (or assent where applicable)
- Diagnosed with chronic urticaria with UAS7 prior to enrollment already on first line of treatment for Chronic Urticaria
- Prescribed Histoglob injections for the first time at the discretion of treating physician as part of routine car
Who cannot take part
- Known allergy or hypersensitivity to Histoglob or human immunoglobulin product
- Patients with acute allergic attack
- History of malignancy or any condition requiring immunosuppressive therapy other than study indication
- Any other condition or circumstance that, in the opinion of the study physician, makes the patient unsuitable for study participation
- Pregnant or lactating women
- Participation in any other clinical study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria in India.
The group in the trial
- Chronic Urticaria Group
Patients with Chronic Urticaria on the first line of treatment like antihistaminics and not controlled requiring histaglobulin treatment
Treatment: Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex; IHC (Histoglob) in the Management of Chronic Urticaria: A Prospective, Multicenter, Observational Study.
- Record updated
- 2 October 2026